New data presented at the Fall Clinical Dermatology Conference showed that Winlevi (clascoterone) cream 1% effectively reduces oil production, remains stable when used with other acne medications, and improves outcomes in skin of color. A study demonstrated a reduction in facial sebum production with Winlevi, with significant reductions in oily face appearance, pore size, and facial shine levels. Results showed a reduction in inflammatory and noninflammatory lesions with high tolerability. Another study evaluated Winlevi’s efficacy in patients with skin of color, showing significant reductions in lesions with no adverse events reported. These findings provide promising results for acne treatment.
Source link
Data showcase efficacy of Winlevi as acne treatment
